{
  "id": 12007104,
  "title": "Vaxcyte to present phase 3 trial data for vaccine candidate",
  "url": "https://urgent.news/2026/10/04/vaxcyte-to-present-phase-3-trial-data-for-vaccine-candidate",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-04T21:04:37.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/vaxcyte-to-present-phase-3-trial-data-for-vaccine-candidate-93CH-4930957"
  },
  "original_language": "en",
  "account": null,
  "summary": "Vaxcyte, Inc., a San Carlos, Calif.-based biopharmaceutical company, will host a conference call on Monday at 8:00 a.m. ET to present the topline data from its OPUS-1 adult pivotal Phase 3 trial for its 31-valent pneumococcal conjugate vaccine candidate, VAX-31. The trial evaluated the safety, tolerability, and immunogenicity of VAX-31, which is designed to prevent invasive pneumococcal disease and pneumococcal pneumonia. The conference call can be accessed through a toll-free number for domestic callers or an international conference ID. VAX-31 is being evaluated in both adult and infant clinical programs, while the company also has a 24-valent pneumococcal conjugate vaccine candidate, VAX-24, with Phase 2 clinical results in adults and infants. Vaxcyte's pipeline includes additional vaccine candidates, such as VAX-XL for expanded pneumococcal coverage, VAX-A1 for Group A Strep prevention in Phase 1 trials, and VAX-GI designed to prevent Shigella. The company utilizes its cell-free protein synthesis platform, XpressCF, licensed from Sutro Biopharma, Inc., for vaccine development.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}